An announcement from IDT Australia Limited ( (AU:IDT) ) is now available.
IDT Australia Limited has secured a five-year, $3.2 million contract with Nacuity Pharmaceuticals for the manufacture of NPI-001, an investigational treatment for retinitis pigmentosa. This contract involves recommissioning IDT’s 4,000L Active Pharmaceutical Ingredient plant, making it the largest small molecule API facility in Australia, which strategically positions IDT to address potential drug shortages and expand its manufacturing capabilities.
More about IDT Australia Limited
IDT Australia Limited is an Australian pharmaceutical manufacturing company based in Boronia, Victoria, known for its expertise in developing and producing high potency and high containment pharmaceutical products for both local and international clients. The company operates cGMP compliant facilities that are regularly audited by the US FDA and Australian TGA, offering comprehensive services for new drug development, scale-up, and commercial manufacturing of various oral and injectable drug forms.
YTD Price Performance: -23.64%
Average Trading Volume: 325,296
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$38.04M
Find detailed analytics on IDT stock on TipRanks’ Stock Analysis page.